Day One Biopharmaceuticals (NASDAQ:DAWN) executives highlighted accelerating commercial momentum for OJEMDA and outlined ...

Servier, an independent international pharmaceutical group, is acquiring Day One Biopharmaceuticals for $21.50 per share in ...

Detailed price information for Day One Biopharmaceuticals Inc (DAWN-Q) from The Globe and Mail including charting and trades.

Biopharmaceuticals, also known as biologics, are a class of medicines produced using living systems such as microorganisms, plant or animal cells, or recombinant DNA technology. Unlike traditional ...

Day One Biopharmaceuticals stock remains a "Strong Buy." Learn more about its outlook, surging revenue, and ADC pipeline catalysts.

The companies entered into a letter of intent in January 2026 regarding a potential transaction in which XTL would acquire Beyond Air’s majority ownership interest in NeuroNOS Ltd. The letter of ...

Day One Biopharmaceuticals (DAWN) has drawn investor attention after strong recent share performance, with returns of 65% over the past week and 81% over the past month, prompting closer review of its ...

Management projected full-year 2025 net product revenues of $140 million to $150 million for OJEMDA, citing "strong and persistent demand, deepening prescriber adoption, and consistent payer coverage" ...

Fintel reports that on March 9, 2026, Wedbush downgraded their outlook for Day One Biopharmaceuticals (NasdaqGS:DAWN) from ...

Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings ...

The global biopharmaceuticals market is projected to grow at a compound annual growth rate (CAGR) of approximately 12% over ...